Both medications can be effective for weight loss, but side effects, health conditions, cost, and personal preference often guide which option is the better fit
Cardiovascular Health : Research indicates that GLP-1 receptor agonists may have cardioprotective effects , improving heart health by regulating lipid levels , reducing inflammation , and improving vascular function
STEP series clinical trials of Semaglutide Novo's two obesity products, Wegovy and Saxenda, have generated DKK 16.86bn (USD 2.5bn) in sales throughout 2022, doubling the preceding year's result of DKK 8.4bn (USD 1.2bn) an increase of 101%
Age-related differences in outcomes Younger adults (18-40) typically achieve faster weight loss and greater total reductions compared to older adults (60+), though older individuals still achieve clinically meaningful results